# Congenital Malignant Ectomesenchymoma Presenting as a Neck Mass in a Newborn

**Authors:** Ianna S. C. Blanchard, Ravi C. Bhavsar, Ashley M. Olszewski, Nathan R. Shelman, John A. D’Orazio, Prasad Bhandary, Thitinart Sithisarn

PMC · DOI: 10.3390/children12040480 · Children · 2025-04-08

## TL;DR

A newborn presented with a rare aggressive tumor in the neck, requiring complex treatment and highlighting the need for early diagnosis and multidisciplinary care.

## Contribution

Reports a rare congenital case of malignant ectomesenchymoma in a newborn with detailed clinical and therapeutic insights.

## Key findings

- The tumor showed rhabdomyoblastic and neuroectodermal differentiation, confirmed by biopsy.
- Initial chemotherapy failed, necessitating a change in treatment protocol.
- Early surgical resection and multidisciplinary care were critical for management.

## Abstract

Background: Malignant Ectomesenchymoma (MEM) is a rare, aggressive soft tissue neoplasm with both neuroectodermal and mesenchymal differentiation. Congenital cases are extremely uncommon, posing significant diagnostic and therapeutic challenges. Case Presentation: We report a case of a full-term male neonate presenting with a large congenital neck mass and respiratory distress at birth. Imaging revealed a lobulated, heterogeneously enhancing mass in the left submandibular region with a mass effect on the airway. Open biopsy and gross resection on day six of life confirmed MEM with rhabdomyoblastic and neuroectodermal differentiation. Post-surgical staging classified the tumor as Stage I, Clinical Group II. Despite initial chemotherapy with Vincristine, Actinomycin, and Cyclophosphamide (VAC), tumor recurrence was detected at week nine of chemotherapy, necessitating a transition to Vincristine, Irinotecan, and Temozolomide (VIT). Discussion: MEM is an extremely rare neoplasm in infants, particularly in congenital presentations. Diagnosis is challenging due to its mixed histopathological features and broad differential diagnosis, including rhabdomyosarcoma, fibrosarcoma, lymphangioma, and neuroblastoma. Management typically involves multimodal therapy, with surgical resection being the mainstay of treatment. Chemotherapy is often tailored to the tumor’s most aggressive component, though standardized treatment protocols remain undefined. Conclusions: This case highlights the importance of early recognition and a multidisciplinary approach in managing congenital MEM, as a differential diagnosis of soft tissue masses in infants, particularly in the head and neck region.

## Linked entities

- **Chemicals:** Vincristine (PubChem CID 5978), Actinomycin (PubChem CID 457193), Cyclophosphamide (PubChem CID 2907), Irinotecan (PubChem CID 60838), Temozolomide (PubChem CID 5394)
- **Diseases:** Malignant Ectomesenchymoma (MONDO:0002855), rhabdomyosarcoma (MONDO:0005212), fibrosarcoma (MONDO:0002676), lymphangioma (MONDO:0002013), neuroblastoma (MONDO:0005072)

## Full-text entities

- **Diseases:** neuroblastoma (MESH:D009447), soft tissue neoplasm (MESH:D012983), Neck Mass (MESH:D006258), fibrosarcoma (MESH:D005354), soft tissue masses (MESH:D017695), lymphangioma (MESH:D008202), respiratory distress (MESH:D012128), Congenital Malignant Ectomesenchymoma (MESH:C565679), MEM (MESH:D009369), rhabdomyosarcoma (MESH:D012208)
- **Chemicals:** Temozolomide (MESH:D000077204), Cyclophosphamide (MESH:D003520), Irinotecan (MESH:D000077146), Vincristine (MESH:D014750), VAC (-), Actinomycin (MESH:D003609)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12025713/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12025713/full.md

## References

12 references — full list in the complete paper: https://tomesphere.com/paper/PMC12025713/full.md

---
Source: https://tomesphere.com/paper/PMC12025713